New findings in Age Related Eye Disease Study
The findings of the Age Related Eye Disease Study (AREDS2) have been recently published.
It has been found that adding omega-3 fatty acids, and lutein and zeaxanthin, or all three to the original AREDS formula does not further reduce the overall risk of progression to advanced age-related macular degeneration.
However, adding the plant derived antioxidants lutein and zeaxanthin benefits certain groups. Those with low dietary intake of lutein and zeaxanthin who took an AREDS supplement with lutein/zeaxanthin were about 25 per cent less likely to develop advanced AMD than patients with similar dietary intake who did not take lutein/zeaxanthin supplements.
Those given an AREDS formula with lutein/zeaxanthin but not beta-carotene reduced their risk of developing advanced AMD by 18 per cent over five years, compared with those given an AREDS formula with beta-carotene but not lutein/zeaxanthin.
The original Age Related Eye Disease Study (AREDS) in 2001 found those taking the combination formula of high dose vitamins C and E, beta-carotene, zinc and copper were 25 per cent less likely to progress to advanced AMD over five years than those on placebo.
Another study found none of the modified AREDS2 versions reduced the risk of progression to cataract surgery but people with low dietary lutein and zeaxanthin gained some protection.
The dose recommended by the AREDS2 study can be obtained by taking an MDEyes antioxidant once daily or alternatively Macuvision Plus tablets twice daily. MDEyes antioxidants are in stock and available at the practice.